SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
Executes the first project for developing and manufacturing a novel anticancer mAb
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
Additional capacity broadens Grace’s fine chemical capabilities for API production
Global TB incidence saw a reduction of 8.7% while in India we were able to demonstrate a reduction of 16%, almost double the pace
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
PharmaLogic will assist ARTBIO with radiochemistry and supply of the finished radiopharmaceutical product for future Phase I and II clinical trials of AB001 from their facility in New York
The R&D centre is mainly dedicated to the Process R&D of New Chemical Entities (NCE) development projects
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
Subscribe To Our Newsletter & Stay Updated
